Planview Acquires AI/ML Leader Aptage
9.7.2020 17:03:00 EEST | Business Wire | Press release
Planview® today announced the acquisition of Aptage, a technology leader and pioneer in the application of Artificial Intelligence (AI) and Machine Learning (ML) to portfolio management and work management.
Aptage’s expertise in data science is combined with unique domain knowledge in the economics of development spanning Agile and project methodologies. The company’s technology and IP is focused on the application of AI/ML to enterprise software, offering customers early insights and visibility into anticipated value and delivery risk across traditional project management and agile methodologies. For Planview customers, this ultimately means more accurate project outcome forecasting, regardless of work methodologies and processes used to get work done.
“In today’s disruptive environment, the companies with early insights are the ones that can pivot more quickly to create competitive advantage,” said Greg Gilmore, CEO of Planview. “Aptage’s innovative AI/ML technology creates insights into project value and delivery risk, improving and strengthening the strategy to delivery pipeline. We’re excited to welcome Aptage into the Planview family and bring this expertise to our customers.”
“Aptage and Planview share a common vision for the future of AI/ML within portfolio management and work management,” said John Heintz, co-founder and CEO of Aptage. “We’re thrilled to be taking this next step together, expanding the reach of our technology and driving better outcomes for organizations.”
Founded in 2016, Aptage’s proprietary IP was designed to accommodate the small data characteristics of Agile and traditional projects to continuously learn, predict, and provide actionable advice throughout the strategy to delivery pipeline. The technology has been proven with early adopters and is ready to scale to the mainstream market with Planview.
John Heintz, co-founder and CEO, and Dr. Murray Cantor, co-founder and CTO, will be joining Planview, bringing extensive experience and unique expertise to the company. Heintz is a recognized thought leader in the Agile and Lean community with 20 years of hands-on experience, and will be joining to lead product management for AI/ML. Dr. Cantor joins Planview as the company’s Chief Data Scientist, a new role created in recognition of the momentum in data science and the application of AI/ML in enterprise software.
Planview will be embedding the Aptage AI/ML IP across the Planview product portfolio. We anticipate the Aptage technology being available to customers later this year. To learn more, visit: Planview.com.
Additional Resources:
- Aptage website
- Register for Planview Horizons– Sept 15-16, 2020
- Follow the Planview Blog
- Connect with Planview on Twitter, Facebook and LinkedIn
About Planview
Planview has one focus: enabling the transformation journey as organizations rewire strategy to delivery in today’s fast-paced, highly disruptive markets. Our solutions uniquely help organizations navigate this journey and accelerate on-strategy delivery at enterprise scale. Planview’s full spectrum of Portfolio Management and Work Management solutions create organizational focus on the strategic outcomes that matter and empower teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enable customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, Planview has more than 700 employees supporting 3,500 customers and 1 million users worldwide. For more information, visit: https://www.planview.com/.
Planview and the Planview logo are registered trademarks of Planview, Inc. All other trademarks are property of their respective owners.
About Aptage
Aptage is a technology leader and pioneer in the application of Artificial Intelligence (AI) and Machine Learning (ML) to portfolio and work management, enabling companies to use their own data more intelligently through schedule, cost, and prioritization solutions. Companies using Agile, Waterfall, or hybrid frameworks have used Aptage to learn more from their project data and make informed business decisions based on AI advice. For more information, visit: https://get.aptage.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200709005606/en/
Contact information
Planview
Leslie Marcotte, 719-439-4921
lmarcotte@planview.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom